This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This KCNQ1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 4-33 amino acids from the N-terminal region of human KCNQ1.
KCNQ1
Reactivity: Human
WB, IHC, IP, IF, ICC, AA
Host: Mouse
Monoclonal
N37A-10 (Formerly S37A-10)
unconjugated
Application Notes
WB: 1:1000
Restrictions
For Research Use only
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date
6 months
Target
KCNQ1
(Potassium Voltage-Gated Channel, KQT-Like Subfamily, Member 1 (KCNQ1))
Alternative Name
KCNQ1
Background
This gene encodes a voltage-gated potassium channel required for the repolarization phase of the cardiac action potential. The gene product can form heteromultimers with two other potassium channel proteins, KCNE1 and KCNE3. Mutations in this gene are associated with hereditary long QT syndrome (also known as Romano-Ward syndrome), Jervell and Lange-Nielsen syndrome and familial atrial fibrillation. The gene is located in a region of chromosome 11 that contains a number of contiguous genes, which are abnormally imprinted in cancer and the Beckwith-Wiedemann syndrome. This gene is also imprinted, with preferential expression from the maternal allele in some tissues, excluding cardiac muscle. Alternatively spliced transcripts encoding distinct isoforms have been described.